KLK1 and urogenital neoplasm: Notably, KLK1 administration to normal rats (NCK group) did not affect their prostate pathological performance and that HOE140 blocking the KLK1/BK signaling pathway (EAPKH group) made the anti-inflammatory effect of KLK1 on prostatitis be canceled (Figure 2(f)).